Company intelligence / Profile preview

GraceFall

Ownership: Private
Development stage: Commercial

Overview

Gracell’s lead asset GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy. In clinical studies, it has shown high overall response rates in relapsed/refractory and newly diagnosed multiple myeloma patients. The company also initiated trials for refractory SLE. The technology aims to deliver faster manufacturing and improved T-cell fitness compared to conventional CAR-T therapies.

Therapeutic areas: OncologyImmunologyHematology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on GraceFall.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GraceFall.

Explore the full profile